aiMH Lab - Association of Long-Acting Injectable Antipsychotics and

Journal article

Yue Wei, Vincent K. C. Yan, Wei Kang, I. Wong, D. J. Castle, Le Gao, C. Chui, K. Man, J. Hayes, W. Chang, E. Chan
JAMA network open, 2022

Semantic Scholar DOI PubMedCentral PubMed

Cite

APA Click to copy
Wei, Y., Yan, V. K. C., Kang, W., Wong, I., Castle, D. J., Gao, L., … Chan, E. (2022). Association of Long-Acting Injectable Antipsychotics and Oral Antipsychotics With Disease Relapse, Health Care Use, and Adverse Events Among People With Schizophrenia. JAMA Network Open.

Chicago/Turabian Click to copy
Wei, Yue, Vincent K. C. Yan, Wei Kang, I. Wong, D. J. Castle, Le Gao, C. Chui, et al. “Association of Long-Acting Injectable Antipsychotics and Oral Antipsychotics With Disease Relapse, Health Care Use, and Adverse Events Among People With Schizophrenia.” JAMA network open (2022).

MLA Click to copy
Wei, Yue, et al. “Association of Long-Acting Injectable Antipsychotics and Oral Antipsychotics With Disease Relapse, Health Care Use, and Adverse Events Among People With Schizophrenia.” JAMA Network Open, 2022.

BibTeX Click to copy

@article{yue2022a,
  title = {Association of Long-Acting Injectable Antipsychotics and Oral Antipsychotics With Disease Relapse, Health Care Use, and Adverse Events Among People With Schizophrenia},
  year = {2022},
  journal = {JAMA network open},
  author = {Wei, Yue and Yan, Vincent K. C. and Kang, Wei and Wong, I. and Castle, D. J. and Gao, Le and Chui, C. and Man, K. and Hayes, J. and Chang, W. and Chan, E.}
}

Abstract

Key Points Question Are long-acting injectable antipsychotics (LAIAs) associated with a lower risk of disease relapse, health care use, and adverse events compared with oral antipsychotics among people in Hong Kong with schizophrenia? Findings In this 16-year, population-based, self-controlled case series study of 70 396 individuals with a diagnosis of schizophrenia, 23 719 were prescribed LAIAs and oral antipsychotics. There were 48% fewer psychiatric hospitalizations, 47% fewer hospitalizations for schizophrenia, 44% fewer suicide attempts, and 37% fewer all-cause hospitalizations during full treatment periods with LAIAs alone, without an increased risk of adverse events; this association was also observed when excluding the first 90 days of treatment. Meaning This study suggests that clinicians should more broadly consider the long-term use of LAIAs for people with schizophrenia.